POLITICA

Zuellig Pharma strengthens competitiveness in Korea with new distribution center in Anseong

zuellig-pharma-strengthens-competitiveness-in-korea-with-new-distribution-center-in-anseong
A bird's-eye view of the new distribution center of Zuellig Pharma Korea
A bird’s-eye view of the new distribution center of Zuellig Pharma Korea

Zuellig Pharma today announced plans to open an additional warehouse and relocate existing operations at the Hwasung 2 distribution center as part of efforts to innovate its distribution operations and capitalize on strong demand for its solutions in Korea. In line with this, the company will lease approx.18,000㎡(5,500 pyeong) in a warehouse building located in Anseong.

Zuellig Pharma currently operates two distribution centers in Hwasung, four in Anseong, one in Gimpo, and also manages five distribution centers owned by affiliated companies for a total of approx. 69,000㎡(20,900 pyeong). The new distribution center in Anseong will feature an automation system and operate according to EcoVadis Platinum sustainability standards. With the relocation of Hwasung 2, Zuellig Pharma will increase operation efficiency across all of its distribution centers so that each focuses on a specific function.

The investment comes as Zuellig Pharma is poised to capitalize on rising demand for Pharmaceutical products including cold-chain solutions in the biologics sector, alongside strong growth in its Clinical Reach business unit, which has experienced growth of over 20% year on year.

“Zuellig Pharma is confident in the growth potential of the Korean business, and we are committed to our mission of making healthcare more accessible here. The new distribution center will have easy geographical accessibility, environmentally friendly elements in accordance with Zuellig Pharma’s ESG management principles, and state-of-the-art automation facilities to better support our clients’ various needs in the market,” says Marc Franck, CEO of Zuellig Pharma Korea.

Work on the Anseong distribution center is scheduled for completion by the end of Q2, 2024.

Leave a Reply